Corelet™ platform: Precision high throughput screening for targeted drug discovery of biomolecular condensates

IF 2.7 4区生物学 Q2 BIOCHEMICAL RESEARCH METHODS

SLAS Discovery Pub Date : 2025-02-28 DOI:10.1016/j.slasd.2025.100224

Aislinn Mayfield , Xin Zhang, Ivan Efremov, Michael G Kauffman, John F Reilly, Bahareh Eftekharzadeh

引用次数: 0

Abstract

Biomolecular condensates (BMCs) are crucial for cellular organization and function, and their dysregulation is linked to neurological, oncologic and inflammatory diseases. This highlights the need for advanced investigative tools leading to targeted BMC therapeutics. To address this need, Nereid Therapeutics uses Corelet™ technology and an automated high-throughput screening (HTS) platform to precisely quantify phase separation events and identify BMC modulators for previously undruggable targets. Hundreds of thousands of small molecules have been screened utilizing Corelet technology, yielding small molecule BMC-modulating compounds which serve as the basis for the development of targeted therapies for diseases with high unmet need.

Abstract Image

查看原文本刊更多论文

Corelet™平台：生物分子凝聚物靶向药物发现的精确高通量筛选。

生物分子凝聚体（BMCs）对细胞组织和功能至关重要，其失调与神经、肿瘤和炎症疾病有关。这突出了对先进的研究工具的需求，从而导致靶向BMC治疗。为了满足这一需求，Nereid Therapeutics使用Corelet™技术和自动化高通量筛选（HTS）平台来精确量化相分离事件，并识别以前不可药物靶点的BMC调节剂。利用Corelet技术筛选了成千上万的小分子，产生了小分子bmc调节化合物，这些化合物可作为开发针对高未满足需求疾病的靶向治疗的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SLAS Discovery Chemistry-Analytical Chemistry

CiteScore

7.00

自引率

3.20%

发文量

审稿时长

39 days

期刊介绍： Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).